BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial
Story so far
Earlier from BioVie
- BioVie Announces Additional Findings from Phase 2 Parkinson’s Disease Trial: More patients treated with NE3107 experienced morning “on state” with levodopa withheld overnight compared to those treated with placebo
- BioVie Announces Completion of Patient Enrollment in Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease
- BioVie Announces “BioVie Day” to be held March 23, 2023
- BioVie Announces Additional Findings from Phase 2 Alzheimer’s Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia
- BioVie Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials
Later from BioVie
- BioVie Announces Registration Details for "BioVie Day" Webinar
- BioVie Announces Data from Phase 2 Parkinson’s Disease Trial Accepted for Presentation at AD/PD 2023
- BioVie Announces Data Abstracts from NE3107 Phase 2 Trials Accepted for Presentation at AAN 2023
- BioVie Set to Join the Russell 2000® and Russell 3000® Indexes
- BioVie to Host Virtual KOL Event on NE3107 in Alzheimer’s Disease on September 7, 2023
Follow BioVie into a list and get an email when it puts out news.
Follow BioVie